Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.

Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Abstract Text:

Stefan Boeck,Andreas Hausmann,Roland Reibke,Christoph Schulz,Volker Heinemann,

Gemcitabine in combination with the oral epidermal growth factor receptor tyrosine kinase inhibitor erlotinib is a new treatment option for patients with advanced pancreatic cancer. The nonhematological side effects of this regimen mainly include diarrhea and skin rash. For each of these drugs, gemcitabine and erlotinib, lung toxicities have been described previously. In this report, we present the first case of a nonlung cancer patient experiencing not only acne-like skin toxicity, but subsequently also severe interstitial lung disease during therapy with gemcitabine and erlotinib. Both therapeutic agents were suspected as a possible cause of this adverse event. An interaction between gemcitabine and erlotinib might have also contributed to the pathogenesis of this pulmonary toxicity. Treatment with high-dose steroids was, however, very effective in our patient and a complete recovery appeared within a few days. Thus, pulmonary side effects should be regarded carefully in pancreatic cancer patients receiving palliative therapy with gemcitabine and erlotinib.

Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Publishing Authors By Initials

S Boeck,A Hausmann,R Reibke,C Schulz,V Heinemann,

For similar heterocyclic compounds: heterocyclic compounds, 2-ring: quinazolines research abstracts see: heterocyclic compounds: heterocyclic compounds, 2-ring: quinazolines research

PUBMED ID PMID:

MEDLINE DATE:

Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Anti-cancer drugs

VOLUME: 18

Page Numbers: 1109-11

Journal Abbreviation: Anticancer Drugs

ISSN: 0959-4973

DAY: 30

MONTH: Oct

YEAR: 2007

Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9100823

Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Keywords Mesh Terms:

KEYWORDS: Quinazolines

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Information

Substance Name: Deoxycytidine

Registry Number: 951-77-9

Grant and Affiliation Information for Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.

AFFILIATION: Department of Internal Medicine III, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Germany. stefan.boeck@med.uni-muenchen.de

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Anticancer Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer Related Publications

• A novel antagonist of CRTH2 blocks eosinophil release from bone marrow, chemotaxis and respiratory burst.
• A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats.
• Association of the human kainate receptor GluR7 gene (GRIK3) with recurrent major depressive disorder.
• Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
• Cholinergic dysfunction in temporal lobe epilepsy.
• Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP.
• Fat emulsions for parenteral nutrition II: Characterisation and physical long-term stability of Lipofundin MCT LCT.
• Fat emulsions for parenteral nutrition. I: Evaluation of microscopic and laser light scattering methods for the determination of the physical stability.
• Gemcitabine in metastatic breast cancer.
• Hypoxia suppresses kainate-induced gamma-oscillations in rat hippocampal slices.
• Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib.
• Phage inactivation of foodborne pathogens on cooked and raw meat.
• Primary advanced unresectable pancreatic cancer.
• Reduced ictogenic potential of 4-aminopyridine in the perirhinal and entorhinal cortex of kainate-treated chronic epileptic rats.
• Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
• Special Communications: State-of-the-Science on Postacute Rehabilitation: Setting a Research Agenda and Developing an Evidence Base for Practice and Public Policy. An Introduction.
• State of the science on postacute rehabilitation: setting a research agenda and developing an evidence base for practice and public policy. An introduction.
• State of the science on postacute rehabilitation: setting a research agenda and developing an evidence base for practice and public policy: an introduction.
• State-of-the-Science on Postacute Rehabilitation: Setting a Research Agenda and Developing an Evidence Base for Practice and Public Policy: An Introduction.
• State-of-the-Science on Postacute Rehabilitation: setting a research agenda and developing an evidence base for practice and public policy--an introduction.
• State-of-the-science on postacute rehabilitation: setting a research agenda and developing an evidence base for practice and public policy. An introduction.
• State-of-the-science on postacute rehabilitation: setting a research agenda and developing an evidence base for practice and public policy. an introduction.
• The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.
• Two-pore-domain potassium channels contribute to neuronal potassium release and glial potassium buffering in the rat hippocampus.
• [Current issues of pediatric audiology. Part I. Etiology and diagnosis of congenital and perinatally acquired hearing disorders]
• [Current problems of pediatric audiology. Part II. Fitting of hearing aids, cochlear implants and care of the child with hearing loss]
• [Hormonal contraceptives and cardiovascular risk. Results of an East German multicenter case control study]
• [Not Available.]
• [Reliability of the Menopause Rating Scale (MRS): Investigation in the German population]
• [Trends of OC use 1980-1999 in a German cohort of women]